Category - Feature

Feature

IMUNON harmonizing life’s blueprint with immune system through DNA-based therapies

IMUNON (NASDAQ:IMNN) is advancing a distinctive approach to treating of some of the world’s most challenging diseases, leveraging a portfolio of proprietary immunology and DNA-based platforms that harness the body’s...

January 7, 2025

Feature

GRIN targeting rare pediatric neurological disorders with precision therapies

Closely held GRIN Therapeutics, a Neurvati Neuroscience company, is advancing promising research and development of precision therapeutics for neurodevelopmental disorders, predominately affecting children from infancy...

December 17, 2024

Feature

Perimeter’s positive topline results signal potential for wide-spread user adoption of next-gen, ultra-high-res, AI-driven imaging tool during breast cancer surgeries

Perimeter Medical Imaging AI (TSX-V:PINK; OTC:PYNKF) is poised to transform cancer surgery, as positive topline results from a pivotal study designed to support the company’s planned FDA premarket approval (PMA)...

December 3, 2024

Feature

Clearmind spearheading novel, life-changing psychedelic solutions for binge behaviors and mental health

Clearmind Medicine (NASDAQ:CMND; FSE:CWY0) is discovering and developing safe, novel psychedelic-derived therapeutic candidates with its new psychoactive molecule, 5-Methoxy-2-aminoindane (MEAI), to address widespread...

November 26, 2024

Feature

Spectral combining diagnostics with targeted therapy in novel approach to septic shock

Spectral Medical (TSX: EDT) is seeking to improve outcomes for millions of patients with life-threatening endotoxic septic shock (ESS), by combining its targeted diagnostic, Endotoxin Activity Assay (EAA), with its...

November 12, 2024

Feature

Creyon Bio reimagining drug development with engineered on-demand oligonucleotide therapies

Closely held Creyon Bio is developing a faster, more cost-effective path to new medicines for rare and common diseases through the AI-enabled engineering of oligonucleotide-based therapies (OBMs) that deliver safe...

October 15, 2024

Feature

OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies

OSE Immunotherapeutics (ISIN:FR0012127173; Mnemo:OSE) is developing and partnering therapies to control the immune system for immuno-oncology (IO) and immuno-inflammation with first-in-class immunotherapies from target...

October 1, 2024

Feature

InfoBionic.Ai innovating a beat ahead with gold standard remote cardiac care

Closely held InfoBionic.Ai, a pioneering virtual cardiac telemetry company, is transforming cardiac patient care by equipping healthcare providers with a sophisticated ecosystem of solutions designed to enhance every...

September 17, 2024

Feature

Model Medicines innovates by bringing together data science and biology to develop drugs

Closely held Model Medicines is spearheading the use of AI to model chemistry and human biology, empowering drug discovery and creating novel, best-in-class therapeutics for diseases with high unmet medical needs at...

September 3, 2024

Feature

Entera Bio’s EB613 Oral PTH(1-34) Tablets Poised to Revolutionize Osteoporosis Care for 200 Million Post-Menopausal Women Globally

Entera Bio (NASDAQ:ENTX) is leveraging a disruptive technology platform called N-Tab to develop first-in-class, once-daily oral tablets of peptides and small therapeutic protein replacement therapies. The company...

August 20, 2024

Category - Feature

Subscribe